Company ProfilePremium

Advanced Human Imaging Limited

Company Profile Analysis

Ticker: AHI.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Advanced Human Imaging Limited - Company showcase

Year Founded & Workforce

2014

19 Employees

Advanced Human Imaging Limited logo

Advanced Human Imaging Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Advanced Human Imaging Limited Overview

Advanced Health Intelligence is a small Perth-based digital-health software developer. It sells smartphone-based biometric health screening to businesses. The technology combines a patented on-device body-dimensioning engine (BodyScan) with licensed facial blood-flow vital-signs technology (FaceScan, licensed from NuraLogix) and licensed AI dermatology (DermaScan, licensed from Triage Technologies). Together these form a "Biometric Health Assessment" (BHA) that estimates cardiometabolic risk, blood biomarkers and fitness. AHI sells this to insurers, telehealth platforms, pharmacies, employers and governments, either as a white-label product or as embeddable SDKs, under a "Digital Health as a Service" model.

The company has a credible IP base: 19 granted patents at FY2023. Commercial traction, however, has been minimal. Operating revenue was A$0.37M in FY2024 (unaudited), and the business has relied on R&D tax refunds and repeated dilutive raises. A sequence of failures to keep its listings has left it as an unlisted company: Nasdaq equity-deficiency delisting in 2024, then ASX removal in 2025 after the FY2024 accounts were never lodged. It is now a distressed, pre-scale health-tech asset.


What the company does

AHI develops software that turns a standard smartphone into a health-screening device. According to its FY2023 Form 20-F (Item 4B) and FY2024 Appendix 4E, its core offerings are:

  1. Body dimension and composition assessment. A full-body "selfie" (front and side images) estimates circumferences, body-fat percentage, waist-to-hip and waist-to-height ratios, and risk of obesity, central obesity and Type 2 diabetes.

  2. Blood biomarker prediction. Algorithms estimate total cholesterol, LDL, HDL, triglycerides, HbA1c, C-reactive protein, fasting glucose and 10-year cardiovascular/mortality risk. These came largely from the August 2022 Vertica Health acquisition.

  3. Transdermal Optical Imaging (TOI). A 30-second facial video estimates heart rate, heart-rate variability, blood pressure, respiration and stress. This uses technology licensed from NuraLogix Corporation and its DeepAffex cloud engine.

  4. On-device dermatological identification. The engine covers 588 skin conditions across 133 categories, including melanoma, and is licensed from Triage Technologies Inc. The underlying Triage software is a Health Canada Class I medical device (June 2020) and is CE-marked under the EU Medical Devices Directive (April 2021).

  5. Atrial fibrillation detection. Smartphone-based AFib detection was first listed as an offering in the FY2024 Appendix 4E.

  6. Health coaching enablement. Partners can deliver therapeutic and non-therapeutic coaching. This capability came largely from the wellteq acquisition, although the wellteq platform itself was shut in Q4 FY2023.

The flagship integrated product is the Biometric Health Assessment (BHA), a multi-step smartphone workflow:

  • FaceScan plus a demographic and lifestyle questionnaire

  • Resting heart rate measured by photoplethysmography (PPG)

  • BodyScan for body composition

  • A three-minute step test for cardiorespiratory fitness

  • Algorithmic risk outputs for cholesterol, HbA1c, CRP and similar markers

The FY2023 20-F claims the BHA produces 61 health outputs from 41 biometric captures across five categories: cardio-respiratory, body composition, estimated blood biomarkers, metabolic health and mental health. Management presentations in 2024 cited 82 health markers. The difference has not been reconciled publicly.

Business and revenue model

Revenue mechanismDescription (FY2023 20-F / FY2024 4E)FY2023 (AUD)FY2024 unaudited (AUD)
SDK – per userFee per enrolled user35,495292
SDK – per scanFee per completed scan2,35326,387
Software subscriptionsAnnual/quarterly/monthly licence504,708107,675
Integration and developmentOne-off implementation fees107,141234,075
Other revenue (mainly R&D tax incentive and finance-related)Non-operating2,140,7402,313,159

AHI describes itself as a B2B "Digital Health as a Service" (dHaaS) provider with a "one-to-one-to-many" structure. AHI licenses its technology to a partner, and the partner owns the relationship with end users. The 20-F lists four ways partners pay:

From 2023, management also moved toward deals priced into the partner's own offering, so AHI is paid regardless of how much end users actually use the technology. One example is the Pharmak Direct digital pharmacy (UAE/Saudi Arabia), where AHI was to earn 1.6% of gross prescription value per Pharmak user (FY2023 20-F risk factors). Large licence-plus-equity structures were also struck. The most notable was the August 2023 China exclusive licence with Changlin Network Technology: a US$10M upfront fee, a US$5M annual fee and a 25% revenue share. No public confirmation has been found that the upfront fee was ever received; an extension was granted in April 2024.

Mix characterisation (analyst view): Revenue is overwhelmingly software and licensing; there are no hardware or physical products. However, "other revenue" (chiefly the refundable Australian R&D Tax Incentive) made up 77% of FY2023 total revenue and 86% of FY2024 total revenue. AHI's reported top line therefore reflects government R&D rebates more than commercial sales.

Value-chain position, customers and end markets

AHI sits at the technology/IP layer of digital health. It supplies embeddable measurement and risk algorithms to platform owners rather than running consumer apps itself. The exception was the wellteq corporate-wellness platform, which AHI acquired in late 2022 and shut in mid-2023.

Customer types and end markets disclosed in the 20-F:

  • mHealth, telehealth and wellness platforms

  • Life and health insurers and reinsurers (the Unisure/SCOR letter of intent)

  • Digital pharmacies (Pharmak Direct)

  • Employers and corporate wellness (via wellteq, Bearn LLC)

  • Governments and population-health programmes (Saudi Arabia via IntelliGen; Singapore Healthcare InnoMatch; China via Changlin)

  • Earlier: fitness and consumer apparel (the BodyScan sizing heritage)

Company's own description, paraphrased (FY2024 Appendix 4E): AHI aims to become a global leader in digital health by using the ubiquity of smartphones to provide health-screening and triage tools to providers, carers, insurers and governments. Its stated mission is better outcomes, better health literacy and earlier detection of chronic disease.

Independent characterisation: AHI is a sub-scale, pre-commercial health-AI licensing business. Its proprietary core (BodyScan) is narrow. A significant part of its headline capability (FaceScan, DermaScan) is licensed from third parties on a non-exclusive basis, which limits defensibility. Its go-to-market has depended heavily on announced memoranda, letters of intent and partner launches that have rarely converted into material recurring revenue. In September 2023 it had to retract an announcement that wrongly implied a relationship with AIG.

Strategy

Stated strategy (themes from FY2023 20-F and FY2024 Appendix 4E)

  1. Become a global digital-health leader in smartphone health screening, focused on early identification of chronic-disease risk and digital triage into "right-care pathways".

  2. Population-scale deployment through governments, explicitly tied to Saudi Vision 2030's Health Sector Transformation Program (via IntelliGen) and China's "Healthy China 2030" agenda (via Changlin).

  3. On-device AI to cut cloud costs, latency and privacy risk. The company cites about 3.7 billion AI-capable smartphones.

  4. Revenue de-risking, by pricing AHI into partner offerings (Pharmak revenue share) instead of relying on end-user usage.

  5. Clinical validation and regulatory approval: the Stellenbosch University study, an FDA 513(g) inquiry, and a long-term aim of FDA 510(k) clearance for the BHA as software as a medical device.

  6. Insurance digital underwriting with Unisure and SCOR, using digital biomarkers in place of blood tests.

Initiatives in the last 24 months (Oct 2024 – Oct 2026) and the preceding build-up

InitiativeDateTarget / detailStatus
ASX reinstatement planJun 2024 – Sep 2025ASX required A$4M of cleared funds plus lodgement of the outstanding reportsFailed: removed from ASX on 1 Oct 2025
Nasdaq appeal and relisting strategyAug 2024 – Jul 2025Restore stockholders' equity above US$2.5M; relist after ASX reinstatementFailed: delisting confirmed 2 Jul 2025
A$15M funding package15 Apr 2024Placement, convertible notes, R&D advance, US shelfPartially executed (about A$2.8M equity and A$1.5M notes received in FY2024)
US$4M convertible note facility30 Jan 2025Working capitalDrawdown status not publicly disclosed
Oakley Capital Partners commitment up to A$5.5M2025 (exact date not confirmed)Placement plus convertible note for reinstatement; also targeted US$6M from strategic investors and up to A$3M in R&D grantsOutcome not publicly disclosed
Cost-reduction programmeFY2023 – FY2025A$4.8M annualised savings after acquisitions (Q4 FY2023); further cuts during FY2024Partly achieved (FY2024 G&A −37%)
MENA expansion2023 – 2025IntelliGen SPV, Pharmak MSA, Bin Farhood introductionsRevenue not disclosed
China licence (Changlin)Aug 2023 – Apr 2024US$10M upfront feeExtension granted Apr 2024; receipt unconfirmed
Leadership reset16 Sep 2025Garnett (science- and insurance-oriented founder) becomes CEOOngoing
Post-delisting planFrom Jul 2025Operate as an unlisted company, seek funding, assess alternative exchangesOngoing; no public update found

ESG commitments: None publicly disclosed.

Medium-term financial targets: In 2023 management said it was targeting cash-flow breakeven in calendar 2023 (Q3 FY2023 commentary). That target was missed by a wide margin. The OneClinic partnership targeted 1 million paid users in its first year after launch; no outcome has been reported. No current guidance exists.

Products & Services

All products sit within the single "technological development" segment.

Pricing levels are not publicly disclosed. The only disclosed commercial rates are:

  • Pharmak Direct: 1.6% of gross prescription value

  • Changlin: US$10M upfront, US$5M annual fee and a 25% revenue share

  • IntelliGen: receives 50% of revenue above AHI's base commercial offering

Product Portfolio

ProductDescription and capabilitiesTarget customerOrigin / IP statusLaunch / latest versionPricing model

BodyScan

On-device "full body selfie": front and side images taken with 10-second countdowns in burst mode. Returns circumferences, total body-fat %, waist-hip and waist-height ratios, Type 2 diabetes, obesity and central-obesity risk. Images are processed and deleted on the device

Insurers, telehealth, fitness, apparel, governments

Proprietary and patented (priority date Dec 2014). Section 513(g) FDA inquiry filed 2023 for obesity identification and tracking

Original MyFiziq product (c. 2015); on-device GPU version and later releases

Per scan, per user, subscription

FaceScan

30-second facial video using transdermal optical imaging. Estimates heart rate, HRV, blood pressure, stress, respiratory rate, and CVD, heart-attack and stroke risk. Processed on the NuraLogix DeepAffex cloud

Telehealth, insurers, pharmacies

Non-exclusive licence and reseller agreement with NuraLogix Corporation

Integrated c. 2020–2021

Bundled within the SDK

DermaScan

AI identification of 588 skin conditions across 133 categories, including all skin-cancer categories. Positioned as a second-opinion tool for clinicians

Telehealth, clinicians, insurers

Non-exclusive licence from Triage Technologies (Health Canada Class I; CE-marked; US patent Dec 2020)

Term sheet Oct 2020; integrated 2021

Bundled within the SDK

CompleteScan (MultiScan platform)

Single SDK bundling BodyScan, FaceScan and DermaScan, with user authorisation, billing events, remote asset download and payment registration. iOS and Android

All partners

Proprietary wrapper

2,021

Per scan / subscription

Biometric Health Assessment (BHA)

Five-step smartphone assessment (FaceScan plus questionnaire, PPG resting heart rate, BodyScan, 3-minute step test, analysis) producing 61 outputs from 41 captures (FY2023 20-F)

Governments, insurers, pharmacies, primary care

Proprietary combination of in-house and licensed components

SDK and app announced 2023 (Q3 FY2023 commentary)

Licence plus per-assessment; revenue share in MENA and China

Health Risk Assessment Report (HRA) / digital blood biomarkers

Estimates total cholesterol, LDL, HDL, triglycerides, CRP, visceral adiposity index, lipid accumulation product, fasting glucose, metabolic-syndrome components, brachial-ankle pulse wave velocity and 10-year CVD risk

Insurers (digital underwriting), population health

From the Vertica Health acquisition (Aug 2022)

2022–2023

Bundled

Atrial fibrillation detection

Smartphone-based detection and monitoring of AFib

Cardiology and telehealth partners

Disclosed in FY2024 4E; IP origin not detailed

FY2024

—

Health coaching enablement (ex-wellteq)

Personalised therapeutic and non-therapeutic coaching and health-literacy programmes

Employers, insurers

From the wellteq acquisition; wellteq platform sales ceased Q4 FY2023

2022; discontinued as standalone 2023

Previously subscription

White-label apps / partner brands

Partner-branded apps embedding AHI technology. TradingView lists associated brands ACTIVATE, HEALTH i CHECK, TINJOY, Nexus–Vita, MVMNT and BEARN, most of which appear to be partner or channel brands rather than AHI-owned products

Channel partners

Mixed

Various

—

“—” = not publicly disclosed.

Financial Narrative

Sources by year:

  • FY2020–FY2021: Kalkine aggregator data and ASX releases (net loss for FY2021 confirmed in the FY2022 annual report)

  • FY2022–FY2023: audited FY2023 Form 20-F and reissued FY2022 annual report

  • FY2024: unaudited Appendix 4E (2 Sep 2024)

FY2020–FY2021 operating revenue comes from an aggregator and should be read as indicative. Where no figure is available for a year, that year is left out of the table rather than estimated.

Income statement

Notes:

  • Gross profit is not reported. AHI presents expenses by nature and has no cost-of-sales line, so a gross margin cannot be calculated.

  • Underlying FY2023 EBITDA adds back A$0.476M of impairment and the A$1.808M Triage fair-value loss.

  • EPS (basic/diluted) for FY2022–FY2024 is not disclosed in the sources reviewed (FY2024 weighted average shares not published). Aggregator data (Macrotrends) shows a loss per ADS but on an inconsistent basis, so it is excluded.

  • Dividends per share: zero in every year. AHI has never paid a dividend (FY2024 4E Note 8). Dividend records shown under the "AHI" code on some Australian portals (2007–2008) belong to Allco HIT Limited, a previous holder of the ticker, and do not relate to this company.

Margins.

Revenue CAGR. Operating revenue grew from A$0.14M (FY2020) to A$0.368M (FY2024), a four-year CAGR of about 27%. The path was erratic: a peak of A$0.65M in FY2023 followed by a 43% decline.

Balance sheet

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue Lines

Revenue line (AUD Mn)FY2022FY2023FY2024

Software income

0.0150.5430.134

Integration and development income

0.1830.1070.234

Operating revenue

0.1970.6500.368

Other revenue (incl. R&D tax incentive)

1.1362.1412.313

Total revenue

1.3332.7902.682

Results by Segment and Segment Margins & Growth (%)

Segment metricFY2022FY2023FY2024

Operating loss (AUD Mn)

-20.07-12.60-3.69

Pre-tax loss (AUD Mn)

-20.08-12.83-4.15

Operating revenue YoY growth (%)

—229.4-43.3

Total revenue YoY growth (%)

—109.3-3.9

Contribution to group revenue (%)

100100100

Group Entities

EntityJurisdictionOwnershipFunctionSource

Advanced Health Intelligence Ltd

Australia

Parent

IP owner, HQ, listed entity (historical)

20-F

Vertica Health (Pty) Ltd

South Africa (Stellenbosch)

100%

Biomarker and risk algorithms, science team

FY2024 4E

Wellteq Digital Health Inc. and subsidiaries

Canada (British Columbia) and others

100%

Former corporate-wellness platform (discontinued Q4 FY2023)

FY2024 4E

Body Composition Technologies Pte Ltd

Singapore

53% (from 7 Feb 2024)

Body-composition IP (licence IP A$3.25M on consolidation)

FY2024 4E

US subsidiary

United States

100%

Named only generically in the 20-F (CFC risk factor)

20-F

AHI UAE / MENA SPV entities

UAE

—

Vehicle for IntelliGen/MENA opportunities

20-F; FY2024 4E

Changlin Network Technology Ltd

China (Shanghai)

50% intended under licence terms

China licensee; equity status unconfirmed

20-F

“—” = not publicly disclosed.

Income Statement

Metric (AUD Mn)FY2020FY2021FY2022FY2023FY2024

Operating revenue

0.140.590.1970.6500.368

Net loss after tax

-5.40-14.06-20.08-12.83-4.15

Income Statement (FY2022–FY2024)

Metric (AUD Mn)FY2022FY2023FY2024

Total revenue incl. other revenue

1.3332.7902.682

Employee expenses

11.765.866.37

General administration

4.173.212.02

Operating loss (EBIT proxy)

-20.07-12.60-3.69

Pre-tax loss

-20.08-12.83-4.15

Income Statement (FY2023–FY2024)

Metric (AUD Mn)FY2023FY2024

Sales and marketing

0.9101.476

Depreciation and amortisation

0.3130.358

EBITDA (operating loss + D&A)

-12.29-3.33

Impairment / (write-back)

0.476-5.375

Underlying EBITDA excl. impairment and Triage fair-value items

-10.00-8.70

Insurance expense

1.8251.120

Finance costs

0.4780.688

Margin (%)

Margin (%)FY2022FY2023FY2024

Operating loss / total revenue

-1,505-452-137

Net loss / total revenue

-1,506-460-155

Net loss / operating revenue

-10,191-1,974-1,127

Balance Sheet

Metric (AUD Mn)FY2022FY2023FY2024

Cash and equivalents

6.012.100.026

Total equity

8.562.033.28

Balance Sheet (FY2023–FY2024)

Metric (AUD Mn)FY2023FY2024

Total current assets

3.250.61

Total assets

8.9115.20

Goodwill

3.214.10

Total intangibles incl. goodwill

4.317.84

Investments (incl. Triage at fair value)

0.766.11

Trade and other payables

3.477.56

Short-term debt (borrowings + interest-bearing)

1.430.65

Long-term debt

0.001.49

Total debt (excl. leases)

1.432.14

Net debt (positive = debt)

-0.672.11

Total current liabilities

6.039.50

Total liabilities

6.8811.92

Working capital

-2.78-8.89

Accumulated losses

-75.30-79.45

Issued capital

76.0179.53

Cash Flow

Metric (AUD Mn)FY2020FY2021FY2022FY2023FY2024

Operating cash flow

-2.70-4.10-9.86-7.37-4.75

Financing cash flow

2.849.1217.084.172.78

Cash Flow (FY2021–FY2024)

Metric (AUD Mn)FY2021FY2022FY2023FY2024

Capex (PP&E)

0.0230.0860.1720.002

Free cash flow (OCF − capex)

-4.12-9.95-7.54-4.75

Returns & Leverage Ratios

Metric (AUD Mn)FY2023FY2024

R&D tax incentive received (in OCF)

2.032.31

Receipts from customers

0.820.13

Proceeds from share issues

5.002.79

Proceeds from convertible notes

1.981.50

Investing cash flow

-0.67-0.10

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2023FY2024

ROE (%, on average total equity)

-242-156

ROA (%, on average total assets)

-144-34

Current ratio (x)

0.540.06

Debt / equity (x)

0.710.65

Asset turnover (operating revenue / avg assets, x)

0.070.03

Region (Qualitative) Overview

Region (qualitative)Evidence of commercial activityTrend

Australia / NZ

HQ; R&D tax incentive (main "other revenue")

Stable government rebates

North America

wellteq (Canada, discontinued); Bearn LLC, OnCore Innovations, Kalibra (USA)

Declining after wellteq closure

Europe

Inter-Psy / Health i Check (Netherlands); Unisure/SCOR LOI

Unclear

Middle East / North Africa

Pharmak Direct (UAE, KSA), IntelliGen (KSA), Bin Farhood Group (UAE)

Stated strategic priority FY2024–FY2025; MSA delayed by the ASX suspension

Asia

Changlin (China; licence fee unconfirmed), BCT (Singapore), Singapore InnoMatch finalist, OneClinic

Stated priority for 2024 funding

Africa

Vertica Health (South Africa); Stellenbosch University study

R&D hub

Share Price & Returns

Reference pointPriceDateSource

ASX all-time low

A$0.030

9 Oct 2017

TradingView

ASX all-time high

A$2.19

3 Mar 2021

TradingView

ASX last traded / suspended price

A$0.092

Early 2024 (suspended until removal on 1 Oct 2025)

InvestSMART / TradingView

Nasdaq IPO marketed range

US$7–9 per ADS (1:7 ratio)

Oct 2021

Renaissance Capital

Nasdaq first-day return

-59.7%

Nov 2021

Renaissance Capital

Nasdaq last ADS price

US$1.50 (1:28 ratio)

2024

Yahoo Finance / Tiger

Change since Nasdaq IPO

-91.13%

At delisting

Simply Wall St

Performance (ASX, %)

Value

——

Last price vs all-time high (Mar 2021)

-95.8——

1-year return to Oct 2026

Not meaningful (no trading)

——

3-year return to Oct 2026

Not meaningful (no trading after early 2024)

——

5-year return to Oct 2026

Not meaningful (no trading after early 2024)

——

Capital Instruments

InstrumentAmount (AUD Mn)Maturity

Current borrowings

0.40

< 12 months

Current interest-bearing borrowings

0.25

< 12 months

Non-current borrowings

1.49

12 months (terms not disclosed)

Lease liabilities

0.31

2026–2028 (office lease, 7.8% IBR)

Deferred acquisition consideration

0.58

Current

US$4M convertible facility (Jan 2025)

Drawn amount not disclosed

—

“—” = not publicly disclosed.

Analyst Conclusions

Guidance and consensus

Management guidance: None. The last stated targets were cash-flow breakeven in 2023 (missed) and 1M paid users via OneClinic (unreported).

Consensus growth expectations: None. There is no active analyst coverage.

Bull case

  1. Hidden asset value. The Triage stake (A$5.55M unaudited) plus BCT licence IP (A$3.25M) and a 19-patent portfolio could exceed the company's entire last market value of about A$20–23M in a trade sale or break-up.

  2. Optionality from large licences. A single funded deal of the Changlin type (US$10M upfront, US$5M a year) would transform a business whose FY2024 operating revenue was A$0.37M.

  3. Lean new cost base under insurance-savvy leadership. FY2024 G&A was cut 37%, and CEO Garnett's insurer background (Metropolitan Health, Bryte) fits the digital-underwriting opportunity with reinsurers such as SCOR.

Bear case

  1. Solvency. Cash of A$25,757 against current liabilities of A$9.50M (30 June 2024), with no audited accounts and no public market to raise equity, points to a high probability of further distress or administration.

  2. Credibility. Unclosed headline deals (Changlin), the AIG retraction, two restatements of FY2022 accounts and the failure to lodge FY2024 accounts undermine trust with partners and investors.

  3. Thin moat. Two of the three headline scans are non-exclusive licences, and rPPG and body-scan SDKs are becoming commoditised as big-tech phones add native health sensing.

Catalysts and monitorables (next 12 months)

  • Publication of audited FY2024 and FY2025 accounts, if any

  • Any capital raise or completed Oakley / strategic-investor funding

  • Confirmation or termination of the Changlin licence and fee receipt

  • A trade sale or monetisation of the Triage stake

  • Any application to list on an alternative exchange

  • FDA 513(g) response or a 510(k) submission

  • Revenue from Pharmak, IntelliGen or Bearn

  • Shareholder communications on solvency or any administration

Analyst verdict

Advanced Health Intelligence, formerly Advanced Human Imaging and before that MyFiziq, is a cautionary example of an innovation-rich but commercially unproven health-tech microcap. Over roughly a decade it built a credible on-device body-dimensioning patent family. It then assembled, through licences and small acquisitions, a broad smartphone health-assessment suite covering vitals, skin, fitness and modelled blood biomarkers. The science appears to be serious, and its use of on-device processing anticipated today's privacy-first AI trend.

The financial record is harder to defend. From FY2020 to FY2024 the company lost about A$56M at the net level and burned about A$29M in operating cash. Its best year produced only A$0.65M of operating revenue (FY2023). Reported revenue has been sustained mainly by the Australian R&D Tax Incentive. Management repeatedly announced transformative deals (a US$10M China licence, MENA government channels, insurer partnerships), but the public record does not show these converting into cash. Governance lapses then compounded the commercial shortfall: a retracted press release, restated accounts, and finally the failure to lodge audited FY2024 accounts. That sequence cost AHI its Nasdaq listing in 2024–2025 and its ASX listing on 1 October 2025.

As of October 2026, AHI should be treated as a distressed private company, not an investable listed equity. Any residual value lies in its patents, its Triage stake and its clinical-insurance know-how. That value is most likely to be realised through a trade sale, recapitalisation or licensing transaction rather than organic growth. For counterparties, the key diligence items are audited solvency, the enforceability of key licences (NuraLogix, Triage) and evidence of paying customers.

Overall stance: High risk / speculative. Information quality is too low and solvency too uncertain for a valuation-based recommendation.


Principal sources consulted

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / datesBackgroundBirth yearTotal remuneration (latest reported)

Dylan R. Garnett

Chief Executive Officer

CEO from 16 Sep 2025; corporate officer from 19 Dec 2022 (Chief Innovation Officer)

Founder of Vertica Health. Former CEO of Metropolitan Health Group, MD of Metropolitan Health Risk Management, COO of Bryte Insurance (2011–2012). BCom(Hons), BSc(Hons)

1976—

Scott Montgomery

Former CEO and Executive Director

CEO Dec 2022 – Sep 2025; left the board Sep 2025

Co-founder and CEO of wellteq. Trained exercise physiologist; about 20 years in B2B health

1982

~240k (Yahoo Finance; currency not stated)

Dr Katherine Iscoe

Co-founder, Executive Director

Co-founder; CEO until Dec 2022

BA, BA, MSc, MSc, PhD

1979

~187k (Yahoo Finance)

Vlado Bosanac

Founder and Head of Strategy

Co-founder (2014)

Corporate strategy

1966

~260k (Yahoo Finance)

Simon Durack

CFO and Company Secretary

From at least 2022

BCom, FCA, FCIS, JP

1962

~182k (Yahoo Finance)

Nick Prosser

Non-Executive Chairman

Chair by Aug 2024 (appointment date not disclosed in sources)

———

Dr Peter Vaughan

Non-Executive Director

From Dec 2022 (former wellteq chair)

Health and digital governance

——

Edward Greissing Jr

Non-Executive Director

—

US-based; joined at Nasdaq listing

——

Terence Stupple

Chief Technology Officer

—

Technology

1979—

Dr Riaan Conradie

Chief Science Officer

Not disclosed (likely joined via Vertica)

PhD

——

Anita Swan

Marketing Director

—

Marketing

——

Nadine Amesz

Head of Operations

—

Operations

——

“—” = not publicly disclosed.

Major Shareholders

Holder categoryStakeDateSource

Management and board (shares, rights and options)

~22.6%

30 Jun 2023

FY2023 20-F

Single largest shareholder (unnamed)

~15.6% of ordinary shares

30 Jun 2023

FY2023 20-F

US residents (incl. ADS holders)

~2.41%

30 Jun 2023

FY2023 20-F

Institutional ownership (top 10)

Not publicly disclosed; negligible institutional presence

——

Competitive Landscape

Competitors by Segment

CategoryCompetitorHQPositioning vs AHI

Camera-based vital signs (rPPG/TOI)

NuraLogix (also AHI's licensor)

Canada

Owns the TOI/DeepAffex IP AHI resells; can sell directly to the same customers

Camera-based vital signs

Binah.ai

Israel

Video-based vitals SDK for insurers and telehealth

Camera-based vital signs

Lifelight (Xim Ltd)

UK

Contactless vitals; NHS pilots

Camera-based vital signs

Shen.AI

Poland / global

rPPG SDK

Smartphone body scanning

3DLOOK

USA / Ukraine

Body measurement for apparel and health

Smartphone body scanning

Bodygram

USA / Japan

Body measurement SDK

Body scanning (hardware and app)

Size Stream / Styku / Fit3D

USA

3D body-composition scanners for gyms and clinics

Skin-AI

SkinVision

Netherlands

Consumer skin-cancer risk app (CE-marked)

Skin-AI

Miiskin / First Derm

Denmark / Sweden

Dermatology apps

Health-risk platforms

dacadoo

Switzerland

Health score and engagement platform for insurers

Big-tech platforms

Apple Health, Google Fitbit, Samsung Health

USA / Korea

Native sensor-based health metrics; potential substitutes

Competitor Detail

MetricAHI FY2024

Operating revenue (AUD Mn)

0.368

Operating revenue growth (%)

-43.3

Net margin vs total revenue (%)

-155

Recent Developments

Note on coverage: * Disclosure largely stopped after AHI's ASX removal on 1 October 2025. As an unlisted company, AHI has no continuous-disclosure obligation, and no material public announcements dated after October 2025 were found. The register therefore covers January 2024 to October 2026 so that it holds enough entries to be useful.

Company Snapshot

$0.2M

Revenue

19

Employees

$14.8M

Market Cap

2014

Founded

South Perth, Australia

Headquarters

SWOT Analysis

Strengths

  • Granted IP: 19 patents across 10 jurisdictions, with 11 more pending (FY2023 20-F).
  • Broad multi-modal capability: the BHA reports 61 outputs from 41 captures (FY2023 20-F). DermaScan covers 588 conditions in 133 categories.
  • Regulated components: Triage's dermatology engine is Health Canada Class I and CE-marked (2020–2021).
  • On-device privacy architecture: images are processed and deleted on the phone, which matters under data-sovereignty rules.
  • Recurring non-dilutive R&D funding: about A$2.0–2.3M a year in R&D tax incentive cash (FY2023 A$2.03M; FY2024 A$2.31M).
  • Clinical and insurance domain team: Vertica founder Garnett (former Metropolitan Health CEO, former Bryte Insurance COO) now leads the company.

Weaknesses

  • Negligible commercial revenue: FY2024 customer receipts were A$128,450.
  • Liquidity crisis: cash of A$25,757 against current liabilities of A$9.50M at 30 June 2024.
  • No audited accounts since FY2023: the FY2024 audit was never completed.
  • Repeated reporting restatements: FY2022 loss restated twice; inconsistent FY2023 loss figures in the FY2024 4E.
  • Dependence on licensed IP: FaceScan (NuraLogix) and DermaScan (Triage) are non-exclusive.
  • Accumulated losses of A$79.4M (FY2024 unaudited) against issued capital of A$79.5M.

Opportunities

  • China licence: if the Changlin fee were ever paid, US$10M upfront plus US$5M a year would exceed all historical operating revenue many times over.
  • MENA government health programmes via IntelliGen and Bin Farhood (Saudi Vision 2030).
  • Insurance digital underwriting with a global reinsurer (SCOR, via the Unisure LOI).
  • Regulatory clearance: the FDA 513(g) inquiry could lead to a 510(k), which would open US clinical markets.
  • Monetising the Triage stake: carried at A$5.55M (FY2024 unaudited) and potentially saleable.
  • Trade sale: IP and team could be sold to a larger digital-health or insurtech group.

Threats

  • No listing: delisted from both Nasdaq (2024/2025) and ASX (1 Oct 2025), so the company cannot raise capital through public markets.
  • Going-concern risk: the expected auditor emphasis of matter was disclosed in the FY2024 4E.
  • Licensor competition: NuraLogix and other rPPG vendors sell directly.
  • Big-tech substitution: native smartphone health features (Apple, Google, Samsung).
  • Reputational damage: the September 2023 AIG retraction.
  • Counterparty risk: in the Changlin deal (SAFE approvals; fee unpaid as of the Apr 2024 extension) and in MENA deals delayed by the suspension (Pharmak).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
5 Jan 2024Bearn LLC signs 3 new partners for a user data-sharing platform using AHI biometricsChannel expansion; shares had jumped 27% on the Dec 2023 Bearn announcement
9 & 17 Jan 2024SEC correspondence; 20-F/A for FY2023 filed 17 Jan 2024Regulatory comment process on the annual report
18 Jan 2024CEO to present at the Microcap Conference, Atlantic City (31 Jan – 1 Feb 2024)US investor outreach
31 Jan 2024Q2 FY2024 quarterly commentary and Appendix 4CCash flows show depletion
Early 2024ASX voluntary suspension pending funding announcements; extended 1 Mar 2024Start of an indefinite suspension (last price A$0.092)
7 Feb 2024BCT stake raised to 53%; consolidatedAdds A$3.25M licence IP
12–13 Mar 2024Nasdaq grants an extension to 6 May 2024 to submit an equity-compliance planDelisting risk rises
11 Apr 2024Extension granted to Changlin to complete funding of the US$10M licence feeKey revenue catalyst delayed
14–15 Apr 2024Pharmak Direct MSA extended 90 days because of the ASX suspensionMENA revenue delayed
15 Apr 2024A$15M funding package; about A$1.95M Oakley placement; convertible notes and R&D advanceLiquidity lifeline
18 Apr 2024H1 FY2024 results: loss A$7.74M (+98% YoY); operating revenue A$122,457; cash A$461,011Deteriorating fundamentals
10 May 2024Nasdaq delisting notification for equity deficiency (shortfall about US$1.15M)Plan to appeal
20 Jun 2024Nasdaq Hearings Panel hearing; ASX sets reinstatement conditions (A$4M cleared funds)Dual-listing crisis
30 Jul / 1 Aug 2024Nasdaq Panel delists AHI effective 30 Jul 2024; appeal lodged by 9 AugLoss of US listing
23 Aug 2024Revised Nasdaq appeal lodged, based on the unaudited balance-sheet improvementAppeal ultimately unsuccessful
2 Sep 2024Unaudited FY2024 Appendix 4E: loss A$4.15M, cash A$25,757; auditor expected to include a going-concern emphasis of matterSevere liquidity stress
30 Sep 2024Deadline for the audited FY2024 annual report missedTriggers the 12-month ASX removal clock
14 & 16 Jan 2025"2024 Annual Report Update" and clarificationAudit not complete
24 Jan 2025Investor presentationStrategy reiterated
30 Jan 2025US$4M convertible note facility announced; Q2 FY2025 Appendix 4CFunding attempt
2025 (date unconfirmed)Oakley Capital Partners commitment up to A$5.5M; pursuing US$6M from strategic investors and up to A$3M in R&D grants; cost reductionsReinstatement funding
2 Jul 2025Nasdaq formally confirms delisting of the ADSsUS listing ends
14 Jul 2025"Nasdaq Update" 6-K: ASX reinstatement priority. ASX warned it might refuse reinstatement; if not reinstated by 5 Feb 2026 the company would be removed, and it would then continue unlisted and consider other exchangesContingency plan disclosed
25 Jul 2025Q3 FY2025 (31 Mar 2025) Appendix 4C lodged about 3 months lateReporting delays
31 Jul 2025Several "Proposed issue of securities" noticesFurther dilution
16 Sep 2025Dylan Garnett appointed CEOLeadership change
Sep 2025Scott Montgomery leaves as directorBoard change
1 Oct 2025ASX removes AHI from the Official List (LR 17.12)Company becomes unlisted
Oct 2025 – Oct 2026No further public market announcements located. Data vendors (Nemo, Feb–Jul 2026) still show stale Refinitiv dataInformation vacuum

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue Line: Total revenue rose from AUD 1.3 Mn in FY2022 to AUD 2.7 Mn in FY2024.
Advanced Human Imaging Limited — Revenue Line
Series (AUD Mn)FY2022FY2023FY2024
Total revenue1.32.82.7
Software income00.50.1
Integration and development income0.20.10.2
Operating revenue0.20.70.4
Other revenue (incl. R&D tax incentive)1.12.12.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.